What compounds target STK17A?

BiohacksAI has identified 31 compounds that interact with STK17A (serine/threonine kinase 17a). Top compounds include: gefitinib, erlotinib, imatinib, alvocidib, tozasertib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is STK17A (serine/threonine kinase 17a)?

STK17A is serine/threonine kinase 17a. It is a molecular target for 31 compounds documented in PubMed bioassay data. UniProt ID: Q9UEE5. NCBI Gene ID: 9263.

STK17A

MOLECULAR TARGET

serine/threonine kinase 17a

UniProt: Q9UEE5 NCBI Gene: 926331 compounds

STK17A (serine/threonine kinase 17a) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting STK17A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	imatinib	5.47	236
4	alvocidib	4.52	91
5	tozasertib	4.33	75
6	ruxolitinib	4.23	68
7	quizartinib	3.99	53
8	midostaurin	3.85	46
9	neratinib	3.66	38
10	abemaciclib	3.66	38
11	nintedanib	3.61	36
12	canertinib	3.53	33
13	pelitinib	3.50	32
14	bms 387032	3.47	31
15	tae 684	3.43	30
16	fedratinib	3.40	29
17	mln 8054	3.33	27
18	sp 600125	3.22	24
19	sulfuretin	3.14	22
20	dovitinib	3.09	21
21	jnj 7706621	3.09	21
22	at 9283	3.09	21
23	lestaurtinib	3.04	20
24	r 406	2.83	16
25	pha 665752	2.71	14
26	kw 2449	2.64	13
27	su 014813	2.20	8
28	enzastaurin	2.08	7
29	tomivosertib	2.08	7
30	sp600125	1.10	2
31	Afatinib	0.69	1

About STK17A as a Drug Target

STK17A (serine/threonine kinase 17a) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented STK17A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

STK17A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.